Ustekinumab

乌司奴单抗

Report date: 2026/05/21 20:00:22
First In Class

Base Information

Drug NameUstekinumab
Drug Alias NameAnti-IL-12/23p40 monoclonal antibody优特克诺人源抗白介素12单克隆抗体(CNTO 1275)注射剂Anti-interleukin-12 p40 monoclonal antibody优特吉努单抗 +[13] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-12 inhibitorsInterleukin-23 inhibitorsInterleukin-12 subunit beta inhibitors
TargetsInterleukin-12Interleukin-23Interleukin-12 subunit beta
Therapy Area/IndicationsPlaque psoriasisType I Leukocyte Adhesion DefectCommon Variable Immunodeficiency +[24] 
Global Approved IndicationsPlaque psoriasisPsoriasisCrohn Disease +[4] 
Approved Indications in ChinaPlaque psoriasis
Original Approved Country/TerritoryUnited States
Original Approved Date2009/09/25
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Innovative MedicineJanssen-Cilag International NvUniversity Medical Center Groningen +[17] 
Inactive CompaniesJanssen-Cilag BvXian Janssen Pharmaceutical LtdCharite University, Berlin, Germany +[9] 
Active IndicationsPlaque psoriasisType I Leukocyte Adhesion DefectDiabetes Mellitus, Type 1 +[13] 
Inactive IndicationsCommon Variable ImmunodeficiencyLupus Erythematosus, SystemicDermatitis, Atopic +[11] 

Other Information

ATC CodeL04AC05
Related LinksWikipediaDrugBankKEGG